Aviragen Therapeutics (AVIR) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St set to climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast to split cable business from media in NBCUniversal, Sky spinoff
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Triller to acquire SpaceX exposure as treasury asset via fund structure
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 6, 2025 4:05 PM ESTSuccessful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV)
Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025
Conference Call at 4:30 pm ET Today
BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year... More
